Remove Competition Remove Healthcare Remove Manufacturing Remove Pharmaceutical manufacturing
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. Ironically, in later times, the intense competition for out-of-patent drugs has subsided, which has led to spiraling rises in generic drug prices and shortages.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 3) policing anticompetitive settlements between competing drug manufacturers. 3) policing anticompetitive settlements between competing drug manufacturers. 5) monitoring access to biosimilars.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

article thumbnail

Pharmaceutical Patents: A Challenge for Malaysia

Contrarian Sales Techniques

While India and Italy are known for their active pharmaceutical ingredient (API) industries and production of generic drugs, other countries such as Brazil, Canada, South Korea, and others also have provisions for the manufacture and sale of generic drugs before the patent expires. of gross domestic product (GDP).

article thumbnail

Top 5 Emerging Trends in Pharma Industry

Medico Reach

The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. Here are some more applications of AI in healthcare and pharma Medicines discovery and design can improve drastically.

Pharma 52
article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

Linked to talent, the presence of good universities is another great sign for life sciences, especially institutions with a focus on healthcare. Real estate options, schools, recreational and cultural amenities, healthcare systems, cost of living, transportation, crime and climate are all key considerations.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines.